Immunology · X-Linked Immunoneurologic Disorders

Care Team, First Visit Prep, and Treatment Strategies

At a Glance

X-linked immunoneurologic disorders require coordinated care from immune, neurologic, transplant, genetic, and other specialists. For some conditions, evaluating for stem cell transplant before severe symptoms or organ damage may improve outcomes, but timing depends on the diagnosis and disease stage.

Managing an X-linked immunoneurologic disorder requires more than a single doctor; it requires a specialized “orchestra” of experts. Because these conditions affect the body’s defenses and the brain’s wiring simultaneously, your care team must be highly coordinated to make the right decisions at the right time ^[1]^[2].

Building Your Care Team

A “complete” care team for these ultra-rare conditions typically includes:

Immunologist: Focuses on the “immuno-” part, managing infections, HLH risks, and immune system function ^[3].
Neurologist: Monitors brain health, movement, and cognitive development. For cALD, a Neuro-radiologist is also essential to accurately read complex brain scans ^[4]^[5].
Hematologist/Oncologist: Manages blood-related issues like the tiny platelets in WAS or the risk of lymphoma in XLP ^[6].
Stem Cell Transplant Specialist: Evaluates if and when a transplant is the right path ^[7].
Genetic Counselor: Helps your family understand the inheritance pattern and risks for other family members ^[8].
Endocrinologist: Specifically for cALD, to monitor and treat adrenal insufficiency ^[9].

Preparing for Your First Appointment

To make the most of your first visit, you should arrive with a “data kit” that allows the team to see the full picture of the disease. Do not rely on hospitals to send these files electronically; bring physical copies if possible.

Imaging (The DICOM Files): For cALD, work with your hospital for a secure electronic image transfer alongside the complete signed radiology report so the specialist can calculate the Loes score themselves ^[10]^[5].
Clinical Genetic Data: Bring the full, signed clinical genetic report, including variant classification and test limitations. The specific “variant” (the exact location of the mutation) can change the treatment plan ^[11].
Lab History: A chronological log of EBV viral loads, platelet counts (including Mean Platelet Volume), and adrenal function tests (ACTH/Cortisol) ^[12]^[13].
Neurologic History: A timeline of when any behavioral changes, school difficulties, or motor issues (like clumsiness) first appeared ^[14].

The Role of Hematopoietic Stem Cell Transplant (HSCT)

For many of these disorders, HSCT (also known as a bone marrow or stem cell transplant) can be a definitive treatment that alters the disease’s progression ^[15]^[16]. It replaces the patient’s malfunctioning immune or metabolic cells with healthy ones from a donor ^[7]. (Note: HSCT does not repair established brain/adrenal disease in cALD, nor is it standard for XMEN).

The Power of Timing

The success of HSCT is heavily dependent on when it is performed.

In cALD: The “optimal window” is before symptoms appear. In some observational studies, boys transplanted while they are presymptomatic (low Loes score, no symptoms) have an 89% survival rate and 72% event-free survival. Once major symptoms or advanced brain damage occur, survival and the chance of a good outcome drop significantly ^[17]^[18].
In XLP1: Survival is much higher (100% in some small studies) when the transplant happens before the patient develops severe symptoms or a major HLH crisis ^[15].
In WAS: Outcomes are generally better when children are transplanted before age 5, highlighting the benefit of early intervention ^[19].

Understanding the Risks

HSCT is a “high-stakes” procedure. It carries risks such as Graft-versus-Host Disease (GVHD)—where the new cells attack the patient’s body—and transplant-related mortality ^[16]^[19]. Conditioning regimens are individualized by disease, donor, and age ^[20]^[21].

Deciding on HSCT is a complex calculation of risk versus benefit. While it is a significant undertaking, for many families, it represents the best hope for a long-term cure ^[22]^[23]. Alongside transplant discussions, ensure your team provides comprehensive daily supportive care, including immunoglobulin replacement, infection prophylaxis, and psychosocial support.

Common questions in this guide

Which specialists should be involved in care for an X-linked immunoneurologic disorder?

Care may involve an immunologist, neurologist, hematologist or oncologist, stem cell transplant specialist, and genetic counselor. People with cerebral X-linked adrenoleukodystrophy may also need a neuroradiologist and endocrinologist to review brain scans and monitor adrenal function.

What should I bring to the first appointment for a rare X-linked disorder?

Bring copies of brain MRI images in DICOM format, signed imaging reports, the complete genetic test report, and a dated record of important laboratory results. A timeline of infections, fevers, behavior or school changes, and motor problems can help the team understand how the condition has developed.

How is the timing of a stem cell transplant decided?

Timing depends on the exact disorder, symptoms, brain imaging, laboratory results, donor, age, and overall health. For cALD, transplant is generally considered before neurologic symptoms or advanced brain damage; for XLP1 and Wiskott-Aldrich syndrome, earlier treatment before severe complications may lead to better outcomes. A transplant does not reverse established brain or adrenal damage in cALD.

What are the main risks of HSCT?

Hematopoietic stem cell transplant can cause graft-versus-host disease, in which donor cells attack the recipient’s tissues, and it can lead to transplant-related death. The preparation regimen also has risks, so the team weighs the expected benefit against these risks and individualizes the plan.

Could gene therapy be an alternative to a stem cell transplant?

Gene therapy may be an option for some X-linked disorders, but eligibility and expected benefits depend on the specific diagnosis, genetic variant, age, disease stage, and treatment center. Ask whether the center has experience with the relevant therapy, such as Skysona or WASKYRA, and how it compares with HSCT for the patient.

What does a Loes score tell us about cALD transplant timing?

The Loes score is an MRI-based measure of how much the brain is affected by cALD. A lower score and no neurologic symptoms may indicate a more favorable transplant window, while gadolinium enhancement and advanced changes can affect whether transplant is still within that window; the transplant team should interpret the score with the full clinical picture.

Get notified when new evidence is published on X-linked immunoneurologic disorder.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Care may involve immunology, neurology and neuroradiology, hematology and oncology, transplant, genetics, and endocrinology for cALD.
Bring DICOM MRI files, signed reports, the complete genetic report, chronological laboratory results, and a neurologic history to the first specialist visit.
HSCT can alter disease progression for some disorders, but its appropriateness and timing depend on the diagnosis, disease stage, donor, age, and overall health.
For cALD, outcomes are generally more favorable when transplant is considered before neurologic symptoms or advanced brain MRI changes; HSCT does not reverse established brain or adrenal injury.
HSCT can cause graft-versus-host disease and transplant-related mortality, so conditioning and the balance of risks and benefits must be individualized.

References (23)

1
Trimodal prehabilitation for hematopoietic stem cell transplantation: A best evidence summary.
Wu D, Xue L, Xu L, et al.
Asia-Pacific journal of oncology nursing 2026; (13()):100993 doi:10.1016/j.apjon.2026.100993.
PMID: 42388228
2
Successful Autologous Bone Marrow Transplantation in Active COVID-19 Patients: Case Report.
Amer R, Sabateen A, El-Hamshary Y, et al.
Transplantation proceedings 2023; (55(3)):543-546 doi:10.1016/j.transproceed.2023.02.032.
PMID: 36967338
3
Comprehensive clinical and immunologic characterization of Wiskott-Aldrich syndrome in Iran: a 10-year cohort study.
Esmaeilzadeh H, Gholami MA, Dehghani SS, et al.
BMC immunology 2025; (26(1)):97 doi:10.1186/s12865-025-00779-4.
PMID: 41345550
4
Adrenoleukodystrophy in the Differential Diagnosis of Boys Presenting with Primary Adrenal Insufficiency without Adrenal Antibodies
Ryalls MR, Gan HW, Davison JE
Journal of clinical research in pediatric endocrinology 2021; (13(2)):212-217 doi:10.4274/jcrpe.galenos.2020.2020.0214.
PMID: 32394691
5
Pediatric X-linked adrenoleukodystrophy: phenotypes, variants, and HSCT outcomes.
Li J, Ying L, Chang G, et al.
European journal of pediatrics 2026; (185(5)).
PMID: 41986485
6
Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
Candotti F
Journal of clinical immunology 2018; (38(1)):13-27 doi:10.1007/s10875-017-0453-z.
PMID: 29086100
7
Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD.
Arnold DE, Nofal R, Wakefield C, et al.
Journal of clinical immunology 2022; (42(1)):36-45 doi:10.1007/s10875-021-01103-6.
PMID: 34586554
8
Atypical Presentation in X-linked Immunodeficiency With Magnesium Defect, Epstein-Barr Virus (EBV) Infection, and Neoplasia (XMEN) Disease: A Case Report and Review of Emerging Therapies.
Madsen M, Sidlow R
Cureus 2025; (17(8)):e91193 doi:10.7759/cureus.91193.
PMID: 41018333
9
X-linked adrenoleukodystrophy and primary adrenal insufficiency.
Cappa M, Todisco T, Bizzarri C
Frontiers in endocrinology 2023; (14()):1309053 doi:10.3389/fendo.2023.1309053.
PMID: 38034003
10
MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines.
Mallack EJ, Turk BR, Yan H, et al.
Journal of inherited metabolic disease 2021; (44(3)):728-739 doi:10.1002/jimd.12356.
PMID: 33373467
11
Whole Genome Sequencing in 25 Families with Suspected Inborn Errors of Immunity: Diagnostic Yield and Clinical Relevance of Genome-wide Analysis.
Lee JK, Jang JH, Kim DR, et al.
Journal of clinical immunology 2025; (45(1)):170.
PMID: 41275043
12
X-linked Adrenoleukodystrophy, The Tunisian Experience.
Nasrallah F, Kraoua I, Zidi W, et al.
Clinical laboratory 2015; (61(10)):1531-6 doi:10.7754/clin.lab.2015.150318.
PMID: 26642716
13
Identification of a novel nonsense mutation (c.1369 C > T) in the WAS gene in a neonate: a case report and literature review.
Deng S, Liu X, Chen S, et al.
BMC pediatrics 2026; (26(1)).
PMID: 41928123
14
Long-term outcome of patients with X-linked adrenoleukodystrophy: A retrospective cohort study.
Tran C, Patel J, Stacy H, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2017; (21(4)):600-609 doi:10.1016/j.ejpn.2017.02.006.
PMID: 28274546
15
Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1.
Tomomasa D, Booth C, Bleesing JJ, et al.
Clinical immunology (Orlando, Fla.) 2022; (237()):108993 doi:10.1016/j.clim.2022.108993.
PMID: 35367395
16
Phenotype, genotype, treatment, and survival outcomes in patients with X-linked inhibitor of apoptosis deficiency.
Yang L, Booth C, Speckmann C, et al.
The Journal of allergy and clinical immunology 2022; (150(2)):456-466 doi:10.1016/j.jaci.2021.10.037.
PMID: 34920033
17
Potential Risks to Stable Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Children With Cerebral X-linked Adrenoleukodystrophy.
Kühl JS, Kupper J, Baqué H, et al.
JAMA network open 2018; (1(3)):e180769 doi:10.1001/jamanetworkopen.2018.0769.
PMID: 30646031
18
Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy.
Chiesa R, Boelens JJ, Duncan CN, et al.
Blood advances 2022; (6(5)):1512-1524 doi:10.1182/bloodadvances.2021005294.
PMID: 34781360
19
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Burroughs LM, Petrovic A, Brazauskas R, et al.
Blood 2020; (135(23)):2094-2105 doi:10.1182/blood.2019002939.
PMID: 32268350
20
Hematopoietic Cell Transplantation Rescues Inflammatory Bowel Disease and Dysbiosis of Gut Microbiota in XIAP Deficiency.
Ono S, Takeshita K, Kiridoshi Y, et al.
The journal of allergy and clinical immunology. In practice 2021; (9(10)):3767-3780 doi:10.1016/j.jaip.2021.05.045.
PMID: 34246792
21
Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan.
Ono S, Okano T, Hoshino A, et al.
Journal of clinical immunology 2017; (37(1)):85-91 doi:10.1007/s10875-016-0348-4.
PMID: 27815752
22
Hematopoietic Stem Cell Therapy for Wiskott-Aldrich Syndrome: Improved Outcome and Quality of Life.
Mallhi KK, Petrovic A, Ochs HD
Journal of blood medicine 2021; (12()):435-447 doi:10.2147/JBM.S232650.
PMID: 34149291
23
Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy.
Eichler F, Duncan C, Musolino PL, et al.
The New England journal of medicine 2017; (377(17)):1630-1638 doi:10.1056/NEJMoa1700554.
PMID: 28976817

This page is for informational purposes about care teams and transplant decisions in X-linked immunoneurologic disorders; it does not constitute medical advice. Your specialists and transplant team must tailor testing, timing, and treatment to the individual patient.